NYSEHealth CareMedical DevicesSnapshot 2026-07-31
Reading BFLY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (3q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 28% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 252% growth a year, above the roughly 18% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 41% in its worst 12-month stretch.
View RiskBFLY's growth depends on achieving revenue growth of 20% to 24% in 2026. Revenue grew 39% year over year, and the last quarter beat expectations. It trades at 20× price-to-sales, while the peer median is 3×. The market is pricing in more growth than we forecast, which looks full. If BFLY cuts guidance after recently raising it, that could hurt credibility. Peer multiples imply a price about 311% below where it trades. This read is provisional.
Trailing returns as of 2026-07-31. BFLY is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 5 analysts currently covering BFLY (as of Jul 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Threatens: Maintain adjusted EBITDA loss guidance for 2026
FDA and reimbursement questions pose risks to financial guidance.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Achieve revenue growth of 20% to 24% in 2026
Stock surge indicates market confidence in future growth.
Advances: Achieve revenue growth of 20% to 24% in 2026
FDA clearance enhances product offering and revenue potential.
Advances: Achieve revenue growth of 20% to 24% in 2026
Revenue target aligns with growth strategy and embedded partnerships.
Delisting threat could severely impact operations.
Threatens: Achieve revenue growth of 20% to 24% in 2026
Preliminary revenue growth of 17% is below target.
Advances: Achieve revenue growth of 20% to 24% in 2026
AI licensing deal likely to enhance growth prospects.
Advances: Achieve revenue growth of 20% to 24% in 2026
Launch of Compass AI expected to boost revenue.
